- Home
- USCB vs ABEO Comparison
USCB vs ABEO Comparison
Compare USCB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- ABEO
- Stock Information
- Founded
- USCB 2002
- ABEO N/A
- Country
- USCB United States
- ABEO United States
- Employees
- USCB N/A
- ABEO N/A
- Industry
- USCB Major Banks
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- USCB Finance
- ABEO Health Care
- Exchange
- USCB Nasdaq
- ABEO Nasdaq
- Market Cap
- USCB 351.4M
- ABEO 247.8M
- IPO Year
- USCB 2021
- ABEO 1980
- Fundamental
- Price
- USCB $17.50
- ABEO $5.91
- Analyst Decision
- USCB Buy
- ABEO Strong Buy
- Analyst Count
- USCB 4
- ABEO 3
- Target Price
- USCB $16.13
- ABEO $18.00
- AVG Volume (30 Days)
- USCB 29.4K
- ABEO 177.3K
- Earning Date
- USCB 01-23-2025
- ABEO 11-14-2024
- Dividend Yield
- USCB 1.15%
- ABEO N/A
- EPS Growth
- USCB 13.14
- ABEO N/A
- EPS
- USCB 1.04
- ABEO N/A
- Revenue
- USCB $71,791,000.00
- ABEO N/A
- Revenue This Year
- USCB N/A
- ABEO N/A
- Revenue Next Year
- USCB $15.26
- ABEO $18,714.71
- P/E Ratio
- USCB $17.06
- ABEO N/A
- Revenue Growth
- USCB 10.04
- ABEO 147.52
- 52 Week Low
- USCB $10.25
- ABEO $3.05
- 52 Week High
- USCB $21.86
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- USCB 40.30
- ABEO 52.49
- Support Level
- USCB $17.47
- ABEO $5.49
- Resistance Level
- USCB $18.18
- ABEO $5.79
- Average True Range (ATR)
- USCB 0.90
- ABEO 0.21
- MACD
- USCB -0.14
- ABEO 0.01
- Stochastic Oscillator
- USCB 31.72
- ABEO 77.97
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.